Across TCGA pan-cancer cohorts, TIGD2 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated TIGD2 data layer compared with 28 for mass-spec protein and 2 for mutation status.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher TIGD2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated TIGD2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
UCEC are the cancer types where TIGD2 mass-spec protein most reproducibly stratifies survival.